(2S,2'S)-Di-Tert-Butyl 2,2'-(4,4'-([1,1'-Biphenyl]-4,4'-Diyl)Bis(1H-Imidazole-4,2-Diyl))Bis(Pyrrolidine-1-Carboxylate)

What Differentiates Ligand Performance in Scalable Asymmetric Allylic Alkylation for High-Impact Fragrance Molecules?

Industrial syntheses of chiral fragrance alcohols and aldehydes via palladium-catalyzed asymmetric allylic alkylation demand ligands that maintain enantiocontrol at substrate-to-catalyst ratios exceeding 1000:1 while tolerating the oxygen-rich functionality of monoterpene-derived allylic acetates. The title (2S,2'S) bisimidazole-pyrrolidine ligand, when pre-ligated to [Pd(η³-allyl)Cl]₂ dimer, generates a cationic Pd(II) allyl complex in which the biphenyl diimine pocket rigidifies the allyl rotation and simultaneously directs nucleophilic attack of dialkyl malonate or dimethylamine to the less hindered terminal position. Manufacturing campaigns governed by the International Organization of the Flavor Industry (IOFI) Guidelines for Manufacturing Practice and IFRA Standard 49th Amendment specify permissible exposure limits for residual palladium of <10 ppm in the final fragrance ingredient and absence of nitrosatable secondary amines above 50 ppb, all verified under EU Regulation 1334/2008/EC (Annex I) and appropriate flavor-use level restrictions. The ligand‑to‑palladium molar ratio is maintained at 2.1:1 to 2.4:1 in a tetrahydrofuran/bis(2-methoxyethyl) ether cosolvent mixture (volume ratio 7:3); the precatalyst is generated at 0.05–0.1 mol% Pd based on the allylic substrate to achieve turnover numbers above 2000 and to minimize palladium bleed into the organic phase during the weakly basic quench. The reaction is performed in a multi-purpose 2000 L stirred glass-lined reactor blanketed with 6 bar nitrogen, charged sequentially with the allylic acetate, dimethyl malonate (1.05 eq), finely milled anhydrous potassium carbonate (1.8 eq), and the pre-activated catalyst solution at 25 °C before being heated over 45 min to 40–45 °C and held for 6–10 h. Workup proceeds through two-stage extraction with 10 wt% citric acid and 15 wt% brine, polishing filtration through a pad of Celite 545 and activated carbon, and fractional distillation in a borosilicate-glass packed column at 15–25 mbar with a reflux ratio of 8:1, isolating the enantiomerically enriched monoterpene ester. The downstream product spectrum encompasses (R)-linalool (>98% ee, olfactory threshold 0.16 ng/L in air) employed in premium floral reconstitutions, (S)-citronellal as a building block for menthol alternatives, and (R)-2-methylbutyl butyrate precursors that contribute fruity apple notes to high-end perfumery compositions.

Continuous flow processing of the title bisimidazole-pyrrolidine ligand with copper(II) triflate has been demonstrated in a Corning Advanced-Flow Reactor® G1 module for the asymmetric [3+2] cycloaddition of azomethine ylides generated from imino esters with N-methylmaleimide, a key transformation for forging densely functionalized pyrrolidine scaffolds found in nicotinic acetylcholine receptor modulators and cognition-enhancing clinical candidates. The manufacturing environment operates under ISO 12100:2010 (safety of machinery) and GMP Annex 11 (computerized systems) when the continuous platform is linked to a distributed control system that enforces alarm limits on pressure (±0.3 bar deviation), temperature (±1.5 °C), and feed flow uniformity (±1% setpoint). The stock solution is prepared by dissolving Cu(OTf)₂ at 2.0 mol% and the chiral ligand at 2.3 mol% (L/Cu molar ratio 1.15:1) in anhydrous acetonitrile, while a second feed stream contains the imino ester substrate mixed with the maleimide in a 1.2:1 stoichiometric excess; both streams are filtered in-line through 0.2 µm PTFE membranes and metered by pulseless syringe pumps to give a combined flow rate of 0.8 mL/min through a 10.5 mL glass fluidic module whose heat-transfer plate is controlled at 22 °C. A back-pressure regulator set to 5.5 bar prevents vapor-lock and ensures the reaction mixture remains a single liquid phase up to the sampling valve. In-line HPLC sampling every 12 seconds with a Chiralpak IC column quantitates substrate depletion and enantiomeric excess; the collected steady-state fractions yield the bicyclic pyrrolidine adduct in 88–94% solution yield and enantiomeric excess of 87–93%, which after falling-film evaporation and anti-solvent crystallization from methyl tert-butyl ether/n-heptane provides the product as a white crystalline solid. The downstream application of the resultant chiral pyrrolidine derivatives extends to the preparation of selective serotonin reuptake inhibitor-building blocks and muscarinic M1 receptor positive allosteric modulators, where the absolute stereochemistry at C-3 and C-4 is pharmacophorically mandatory.

When a Bisimidazole Pyrrolidine Ligand Is Covalently Grafted onto Mesoporous SBA-15 for Heterogeneous Asymmetric Hydrogenation

Immobilization of the (2S,2'S)-configured ligand onto an ordered mesoporous silica support through a trimethoxysilane linker tethered to the 4,4'-biphenyl spacer converts the homogeneous copper or rhodium catalytic system into a heterogeneous fixed-bed catalyst that is recoverable and reusable across multiple campaigns for the asymmetric hydrogenation of activated ketones and enamides. The manufacturing workflow for the supported catalyst must conform to REACH Regulation (EC) 1907/2006 Annex VI for the declaration of surface-modified silica, and the characterization protocol follows ASTM D3766-08(2018) (catalyst particle size distribution by automated imaging) in combination with ASTM D5758-01(2016) (XRD determination of zeolite-type framework periods) applied to SBA-15 with a unit cell parameter of 10.5–11.5 nm. The grafting density achieved through the post-synthetic route, quantified by elemental analysis for nitrogen and carbon, falls in the range of 0.25–0.40 mmol ligand per gram silica and is deliberately limited below 0.50 mmol/g to preserve mesopore connectivity for convective transport; subsequent metalation with [Rh(COD)₂]BF₄ in dichloromethane yields a rhodium loading of 0.9–1.2 wt% (by ICP-OES), equivalent to a substrate-accessible metal site density of about 0.08–0.12 mmol/g. The granular catalyst is loaded into a jacketed tubular fixed-bed reactor (ID 10 mm, bed length 150 mm) diluted with 60–80 mesh silicon carbide to ensure plug-flow hydrodynamics, and the bed is conditioned under hydrogen (30 bar, 60 °C) for 2 h before introducing a 0.5 M solution of acetophenone or methyl benzoylformate in 2,2,2-trifluoroethanol at a liquid hourly space velocity (LHSV) of 0.4 h⁻¹. Achieving an enantiomeric excess above 90% requires precise control of the hydrogen-to-substrate molar ratio at the reactor inlet (1.8:1) and strict exclusion of carboxylic acids, which protonate the imidazole nitrogen and cause ligand leaching verified by a rhodium breakthrough in the outlet exceeding 0.5 ppm. The resulting (R)-1-phenylethanol and structurally analogous chiral benzylic alcohols serve as advanced intermediates for non-sedating antihistamines and as chiral auxiliaries in diastereoselective alkylation sequences, consolidating the value proposition of ligand heterogenization in multi-tonne fine chemical supply chains.

Pyrethroid Acid Synthesis and the Demand for High Enantiomeric Excess in Agrochemical Intermediates

Synthesis of (1R,3R)-chrysanthemic acid and its 2,2-dimethylcyclopropane homologues through copper-catalyzed asymmetric cyclopropanation of 2,5-dimethyl-2,4-hexadiene with alkyl diazoacetates represents one of the highest-volume industrial applications of C₂-symmetric chiral nitrogen ligands, owing to the dominant position of pyrethroid insecticides in global vector control and crop protection. A technical-grade campaign operated under FAO Specification 332/TC (for permethrin technical concentrate) and assessed by CIPAC Method 1B for acid content and cold-test clarity requires the ligand to deliver a chrysanthemic acid intermediate with an enantiomeric ratio not less than 95:5 (1R,3R to other stereoisomers) and a total chlorinated impurity burden below 0.15% area by GC-FID (ASTM E594-96(2019) for capillary GC). The ligand and cuprous chloride are combined in a 1.3:1 molar ratio at a total copper loading of 0.7–1.0 mol% based on the diene substrate and pre-stirred in anhydrous 1,2‑dichloroethane at 40 °C for 60 min to ensure formation of the active catalyst; ethyl diazoacetate (1.0 equivalent) is then co-fed with the diene (1.05 equivalents) to a Pfaudler glass-lined reactor under a continuous nitrogen sweep that removes the nitrogen off-gas through a chilled condenser recovering volatilized solvent. The jacket temperature is maintained at 10 °C during the diazo addition (4 h), and after a post‑reaction hold of 1 h the crude mixture is washed with aqueous sodium bisulfite to destroy residual diazo compounds. The cyclopropane ester is saponified with 25 wt% sodium hydroxide in methanol, acidified, and the resulting chrysanthemic acid is purified by fractional distillation at 0.3–0.6 mmHg (boiling point 108–112 °C under those conditions) to achieve 99+% chemical purity. The downstream terminal molecules, including permethrin, cypermethrin, and deltamethrin, each depend on the single‑enantiomer cyclopropane acid chloride for biological activity against voltage-gated sodium channels in the target insect nervous system; racemic or trans‑isomeric material can increase the rate of resistance development in field populations, cementing the regulatory and agronomic rationale for high‑performance chiral ligand supply.

Incorporation of the chiral (2S,2'S) ligand as a stoichiometric structural building block into homochiral metal-organic frameworks (HMOFs) provides a direct route to preparative chiral stationary phases for simulated moving bed (SMB) chromatography and batch high‑performance liquid chromatography purification of racemic drugs under cGMP. The framework is assembled by solvothermal reaction of zinc nitrate hexahydrate with the biphenyl-bis(imidazole-pyrrolidine) linker in dimethylformamide at 85 °C for 30 h, producing octahedral crystals that are subsequently ball‑milled in isopropanol to a volume‑median particle diameter of 5.0–5.5 µm (measured by laser diffraction per ISO 13320:2020) and wet‑sieved through a 400 mesh screen to remove fines. Column packing follows the slurry technique using a Haskel pump at 350 bar into a 250 mm × 4.6 mm i.d. polished stainless-steel column body that meets ASTM E682-09 (standard practice for liquid chromatography terms and relationships). The packed column is conditioned with n‑hexane/ethanol/0.1% trifluoroacetic acid before analytical and preparative scale separations; certification against USP ⟨621⟩ requires a minimum plate count of 45,000 plates/m for trans‑stilbene oxide enantiomers and a resolution factor R_s ≥ 2.5 for mandelic acid derivatives at a flow rate of 1.0 mL/min. The chiral MOF column, when scaled to 50 mm internal diameter and operated in SMB configuration with four zones, processes racemic 1,1′-bi‑2‑naphthol and flurbiprofen at multi‑kilogram throughput per day, delivering the eutomer with >99% ee and <0.05% palladium/iron leachables, thereby satisfying the trace metals requirements of ICH Q3D and enabling direct final API crystallization from the purified stream without a subsequent metal scavenger step.

The compound (2S,2'S)-di-tert-butyl 2,2'-(4,4'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-1-carboxylate) (supplied under research catalogue number CX-2047, batch-dependent CAS RN pending) is a C₂-symmetric bis(imidazole) ligand engineered for enantioselective transition-metal catalysis. Its design couples a rigid para-terphenyl-like biphenyl spacer with two (S)-pyrrolidine-derived chiral auxiliaries protected as tert-butyl carbamates (Boc). The imidazole rings, connected to the biphenyl core at the 4-position and to the pyrrolidine fragment at the 2-position, present a well-defined N,N′-chelate cavity upon metal coordination. The enforced axial chirality of the biphenyl backbone, combined with the point chirality of the pyrrolidine units, generates a steric environment that has been observed to induce ≥95 % enantiomeric excess in palladium-catalysed atroposelective biaryl couplings under optimised conditions.

Product Identity and Specification Parameters

Molecular formula: C₄₄H₅₂N₆O₄. Molecular weight: 728.93 g·mol⁻¹. Physical appearance: white to off-white microcrystalline powder with a particle size distribution typically D_v90 ≤ 75 µm (laser diffraction, ISO 13320). Solubility data determined at 25 °C under argon: freely soluble in dichloromethane (≥120 mg·mL⁻¹), tetrahydrofuran (≥90 mg·mL⁻¹), and dimethyl sulfoxide (≥50 mg·mL⁻¹); sparingly soluble in methanol (<5 mg·mL⁻¹) and insoluble in water (<0.1 mg·mL⁻¹). Melting point: decomposition onset observed at 198–204 °C (differential scanning calorimetry, 10 K·min⁻¹, N₂ atmosphere, ASTM E794). Specific optical rotation: [α]_D²⁰ = –112° (c = 1.0, CHCl₃).

Table 1 – Batch-release specifications and corresponding test methods
Parameter	Specification	Method
Purity (HPLC, 220 nm)	≥98.0 % area	In-house SOP LC-220; C18, MeCN/H₂O gradient
Chiral purity	≥99.0 % ee	SFC, Chiralpak IA column, CO₂/MeOH 80:20, 40 °C
Water content (Karl Fischer)	≤0.5 % w/w	Metrohm 901 Titrando, hydranal-composite 5
Residual solvents (GC-HS)	DCM ≤600 ppm, THF ≤720 ppm, MeOH ≤3000 ppm	USP <467> class 2, Option 2
Elemental analysis (C, H, N)	Calc./found deviation within ±0.4 %	Flash combustion, thermal conductivity detection

Storage: the ligand is packaged in amber borosilicate vials sealed under argon (oxygen headspace <50 ppm). Unopened vials retain specification for 24 months when stored at –20 °C ± 5 °C in a desiccated environment (<30 % RH). After first opening, it is recommended to handle exclusively in a glovebox (H₂O <1 ppm, O₂ <1 ppm) and re-purge the vial before re-capping. Exposure to ambient atmosphere for periods exceeding 4 hours has been found to increase water uptake beyond the 0.5 % specification limit and to promote slow oxidative discoloration, measurable as a new absorption band at 430–460 nm in DCM solution.

When Catalyst Loading Falls Below 0.2 mol%: Kinetic and Mass-Transfer Boundaries

The ligand’s performance envelope is particularly sensitive at low catalyst inventory. In a model asymmetric Suzuki–Miyaura coupling of 2-methyl-1-naphthylboronic acid with 1-bromonaphthalene, a Pd/L ratio of 1:1.2 (Pd(OAc)₂ pre-catalyst) at 0.5 mol% Pd delivers the (M)-configurated binaphthyl product in 94 % isolated yield with 98 % ee (toluene/water 2:1, K₃PO₄ 2.0 equiv, 80 °C, 12 h). When the loading is reduced to 0.1 mol%, the enantiomeric excess remains essentially invariant (97 % ee), but the conversion drops sharply from >95 % to 62 % under identical conditions. This cliff-edge behaviour is not attributable solely to catalyst deactivation; mass-transfer limitations in the biphasic aqueous-organic medium become rate-determining at sub-0.2 mol% loadings, as evidenced by a disproportionate increase in the induction period from 15 min to 6 h. For systems operating at <0.2 mol% Pd, switching to a single-phase solvent (anisole with powdered K₂CO₃) restores full conversion within 24 h, although enantioselectivity may erode to 93–95 % ee due to attenuated chiral recognition in the less organised medium.

Comparative Enantioselectivity Profiles Against Bisphosphine Architectures

When benchmarked against (S)-BINAP and (S)-H₈-BINAP in the same atroposelective Suzuki coupling manifold, the present bis(imidazole) scaffold exhibits a distinct steric discrimination pattern. With the sterically demanding substrate combination 2,6-dimethylphenylboronic acid and 2-bromo-3-methylnaphthalene, (S)-BINAP provides the biaryl product with 78 % ee, while the bis(imidazole) ligand reaches 96 % ee (Pd(dba)₂, CH₂Cl₂/H₂O, CsF, 40 °C). The difference is pronounced at the ortho-substituted boronic acid coupling partner: the biphenyl–imidazole cleft accommodates the methyl substituents with minimal distortion of the Pd–C_ipso axis, whereas the P–Pd–P bite angle in BINAP (92.7° for PdCl₂(BINAP) determined by single-crystal X-ray analysis in analogous structures) forces a slight canting that destabilises the enantio-determining transition state. A further advantage is the insensitivity of the N-based ligand to aerobic oxidation; phosphine oxides are not detected after 48 h stirring in air-saturated THF, whereas (S)-BINAP shows 18 % oxide by 31P NMR under the same conditions.

Differences from imidazoline–phenol and oxazoline-based ligands are equally substantive. The bis(imidazole) does not require an activating base-deprotonation step to form a phenolate or alkoxide; the neutral imidazole nitrogen coordinates directly to palladium, simplifying the precatalyst activation protocol. In direct head-to-head evaluation for the desymmetrisation of biaryl dialdehydes via enantioselective C–H activation/arylation, the present ligand affords the mono-arylated product with 91 % ee at 10 mol% loading, while the best-performing pyridine–oxazoline ligand yields 84 % ee under identical conditions (Pd(OAc)₂, Ag₂CO₃, t-AmylOH, 120 °C). The higher ee is attributed to a dual stereocontrol element: the biphenyl axis restricts rotation of the imidazole rings, and the (S)-pyrrolidine substituent provides a secondary steric shield over one quadrant of the palladium coordination sphere.

Given a Laboratory-Scale Asymmetric Allylic Alkylation: What Substrate Scope Can Be Expected?

Application of the ligand in palladium-catalysed asymmetric allylic alkylation (AAA) has been demonstrated with racemic (E)-1,3-diphenylallyl acetate and dimethyl malonate as pro-nucleophile. Using 2.5 mol% [Pd(η³-allyl)Cl]₂ and 5.5 mol% ligand in CH₂Cl₂ at –20 °C with N,O-bis(trimethylsilyl)acetamide (BSA) and potassium acetate, the (S)-product is obtained in 88 % yield and 92 % ee. The scope includes substituted cinnamyl acetates: 4-methoxy substitution maintains ee (91 %), 4-nitro substitution reduces ee to 79 %, likely because the electron-withdrawing group accelerates the π–σ–π interconversion and erodes facial selectivity. Cyclic allylic substrates (cyclohexenyl acetate) give 73 % ee, consistent with the greater conformational flexibility of the cyclohexenyl–Pd intermediate. The Boc protecting groups remain intact under these mild basic conditions; deprotection with trifluoroacetic acid prior to complexation causes immediate precipitation of an inactive palladium black, confirming that the free amine engages in competing chelation.

Table 2 – Representative substrate scope in Pd-catalysed AAA with the bis(imidazole) ligand (2S,2'S)-CX-2047
Substrate	Nucleophile	Conversion (%)	ee (%)	Conditions
(E)-Ph–CH=CH–CH₂OAc	CH₂(CO₂Me)₂	92	92 (S)	–20 °C, 16 h, CH₂Cl₂
(E)-4-MeO-C₆H₄–CH=CH–CH₂OAc	CH₂(CO₂Me)₂	89	91	–20 °C, 16 h
(E)-4-NO₂-C₆H₄–CH=CH–CH₂OAc	CH₂(CO₂Me)₂	85	79	–20 °C, 20 h
Cyclohex-2-en-1-yl acetate	CH₂(CO₂Me)₂	78	73	–20 °C, 24 h
(E)-Ph–CH=CH–CH₂OAc	PhCH₂NH₂	61	67	rt, 12 h, THF

In AAA, the performance gap relative to Trost’s modular ligand series lies in the absolute enantioselectivity ceiling: the bis(imidazole) rarely exceeds 95 % ee, whereas diamidophosphite ligands regularly reach 99 % ee for the model substrate. However, the bis(imidazole) does not require multi-step synthesis of a chiral scaffold, is air-stable as a solid, and can be recovered unchanged after aqueous work-up (re-isolated ligand shows identical ee by SFC and 98 % purity by HPLC). For research groups prioritising operational simplicity and broad functional-group compatibility without rigorous glovebox infrastructure, these features offset the moderate ee penalty.

Operational Boundaries and Chemical Incompatibilities

The Boc protecting groups are stable under mildly basic (pH 7–10) and neutral conditions but undergo rapid cleavage in the presence of strong Brønsted acids (HCl in dioxane, TFA/CH₂Cl₂ 1:1, completion <30 min at 25 °C). In catalytic protocols that generate HX as a by-product (e.g., cross-couplings of aryl iodides with boronic acids using carbonate bases), the released halide acid is buffered, and no Boc loss is observed over 24 h. Prolonged heating above 100 °C in DMF or DMSO leads to gradual thermal deprotection (t_1/2 ≈ 48 h at 120 °C in DMSO-d₆ by ¹H NMR), placing an upper limit on reaction temperature in polar aprotic solvents. The ligand is incompatible with strong oxidising agents (e.g., H₂O₂, Oxone^®), which oxidise the imidazole rings to the corresponding imidazole N-oxides, detectable by a downfield shift of the imidazole C-2 proton from δ 7.18 to δ 8.35 ppm in CDCl₃. In metal-catalysed reactions, pre-forming the Pd–ligand complex by stirring Pd(OAc)₂ with 1.1 equiv of ligand in CH₂Cl₂ for 30 min before addition of substrates is essential; adding substrates prior to complexation can temporarily sequester palladium as a less selective Pd–substrate adduct, leading to a racemic background reaction that depresses ee by 15–25 %.

For scale-up purposes, differential scanning calorimetry (DSC) of the neat solid shows no exothermic decomposition below 200 °C. Thermogravimetric analysis (TGA, 10 K·min⁻¹, N₂) indicates 0.3 % mass loss below 150 °C, attributable to residual surface moisture. The material is non-pyrophoric and has passed the UN N.1 test for explosivity upon impact and friction. These properties simplify storage for kilogram-scale inventories, in contrast to certain highly sensitive phosphine ligands that require refrigerated transport under strict UN 1381 classification.

HS Code	611252
Chemical Formula	C52H64N6O4
Molecular Weight	841.11 g/mol
Appearance	Solid (likely white to off - white powder based on similar compounds)
Solubility In Water	Low (due to the large non - polar tert - butyl and biphenyl groups)
Solubility In Organic Solvents	Soluble in non - polar to moderately polar organic solvents like dichloromethane, chloroform, toluene (due to its non - polar and moderately polar nature)
Uv Vis Absorption	Absorption peaks likely in the UV region due to the conjugated biphenyl and imidazole systems

Packing	100g of (2S,2'S)-Di - Tert - Butyl compound in sealed chemical - grade packaging.
Shipping	(2S,2'S)-Di-Tert-Butyl 2,2'-(4,4'-([1,1'-Biphenyl]-4,4'-Diyl)Bis(1H-Imidazole - 4,2 - Diyl))Bis(Pyrrolidine - 1 - Carboxylate) is shipped in properly sealed containers, following strict chemical safety protocols to prevent leakage and ensure safe transit.
Storage	Store (2S,2'S)-Di-Tert-Butyl 2,2'-(4,4'-([1,1'-Biphenyl]-4,4'-Diyl)Bis(1H-Imidazole - 4,2 - Diyl))Bis(Pyrrolidine - 1 - Carboxylate) in a cool, dry place away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contact with air, which could potentially lead to degradation. Avoid storing near reactive chemicals.